Description of studies investigating productivity loss due to lymphatic filariasis.

<p>Description of studies investigating productivity loss due to lymphatic filariasis.</p

Description of studies investigating productivity loss due to soil-transmitted helminths.

<p>Description of studies investigating productivity loss due to soil-transmitted helminths.</p

Summary of flowcharts for all PCT NTDs.

<p>Summary of flowcharts for all PCT NTDs.</p

Description of studies investigating productivity loss due to schistosomiasis.

<p>Description of studies investigating productivity loss due to schistosomiasis.</p

Description of studies investigating productivity loss due to onchocerciasis.

<p>Description of studies investigating productivity loss due to onchocerciasis.</p

Results of database searches.

<p>Results of database searches.</p

Global economic benefit or reaching the targets for STH (point estimates), per disease sequela for the period 2011–2030 (billions I$—international dollars)

<p>STH is the disease responsible for the largest economic impact, especially the anemia sequela. The 2.5 and 97.5 percentiles calculated in the sensitivity analysis are shown in the diagram.</p

Productivity loss due to skin disease from onchocerciasis according to the counterfactual and target achievement scenarios (millions I$—international dollars)

<p>Total global loss per year in the counterfactual scenario (blue) and target achievement scenario (orange). The economic benefit is the difference between both scenarios.</p

Direct costs used for lymphatic filariasis with lower and upper limits [between brackets].

<p>Direct costs used for lymphatic filariasis with lower and upper limits [between brackets].</p

Global economic benefit (productivity loss prevented) for the period 2011–2030 (billions I$—international dollars)

<p>Global economic benefit from reaching the targets for 5 PCT diseases, lower and upper estimates from sensitivity analysis.</p